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Abstract
I In nt tr ro od du uc ct ti io on n: :   Cigarette smoking has a negative effect on body reserve of antiox-
idants and cholesterol metabolism. Coenzyme Q10 (CoQ10), a potent antioxidant
synthesized as part of the cholesterol pathway, is a potential biomarker for sys-
temic oxidative stress. We aimed to investigate gender variation in plasma lipid
profile and CoQ10 concentrations in healthy non-smokers and in smokers. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study included 55 cigarette smokers (25 females
and 30 males) and 51 non-smokers (25 females and 26 males) with the age
range from 21 to 45 years, and who had no history of alcohol abuse or chronic
diseases such as diabetes mellitus or obesity. Coenzyme Q10 plasma concen-
trations were measured by reverse-phase high performance liquid chromatog-
raphy (HPLC) with ultraviolet detection. Fasting plasma glucose and lipid levels
were determined by standard colorimetric methods.
R Re es su ul lt ts s: :   Our results showed that CoQ10 concentrations were significantly
decreased in smokers, especially in females, than their non-smoker counter-
parts. Female smokers also exhibited a significant decrease in plasma concen-
trations of total cholesterol (TC), HDL-C, LDL-C, and atherogenic ratios HDL-C/TC
and CoQ10/LDL-C than male counterparts. Plasma triglyceride concentrations
were increased in smokers irrespective of gender. Plasma CoQ10 was relatively
more associated with TC and LDL-C in female smokers than male smokers.
C Co on nc cl lu us si io on ns s: :   The adverse effects of smoking on body reserve of antioxidants
and cholesterol metabolism are greater in females than in males, partially as
a result of decreased CoQ10 plasma concentrations, HDL-C and total-cholesterol
and abnormal atherogenicity indices. 
K Ke ey y   w wo or rd ds s: :   coenzyme Q10, cigarette smoking, total cholesterol, low density lipopro-
tein, high density lipoprotein, triglycerides.
Introduction
The majority of respiratory system cancers and pulmonary vascular dis-
eases are attributable to cigarette smoking [1, 2]. Smoking is also linked
to cardiovascular diseases [3], stroke [4] and fertility disorders [5]. More-
over, an increased risk of mortality from cardiovascular diseases and can-
cer has been associated with cigarette smoking and exposure to cigarette
smoke [6-8]. Prior studies examining the relationship between all-cause
mortality and cigarette smoking have identified gender differences [9];
and alteration of cholesterol metabolism [10, 11] as significant contribut-
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ing factors to the increased risk of death among
active smokers. 
Coenzyme Q10 (CoQ10), a lipid-soluble compound
synthesized as part of the cholesterol pathway, is an
essential cofactor in the mitochondrial respiratory
chain, apotent antioxidant, and apotential biomarker
for systemic oxidative stress [12-14]. Deficiencies in
plasma CoQ10 have been reported in many patient
groups, including certain cardiovascular [15], neuro-
logical [16], hematological [17], neoplastic [18], renal
[19], and metabolic diseases [20]. Moreover, plasma
CoQ10 concentration is an independent predictor of
mortality in chronic heart failure [21].
Previous studies have reported controversial
effects of smoking on CoQ10. Smoking has been
shown to be positively associated with plasma
CoQ10 [22, 23], whereas other studies reported no
association [24, 25] or a negative association with
plasma CoQ10 levels [26]. Numerous factors have
been suggested to contribute to this controversy,
including gender, the levels of plasma cholesterol
and triglycerides [25]. Therefore, we aimed to deter-
mine changes in CoQ10 concentration induced by
cigarette smoking in healthy subjects and to inves-
tigate the possible association of plasma CoQ10 with
gender and lipid profile.
Material and methods
R Re ea ag ge en nt ts s   
Methanol, ethanol and n-propanol were HPLC
grades obtained from BDH (BDH Chemicals, Poole,
Dorset, UK). Pure Coenzyme Q10 and benzoquinone
were obtained from Sigma (St. Louis, MO, USA) and
used as standard. Reagent kits for the analysis of
blood glucose, total cholesterol, LDL-C, HDL-C and
triglycerides were purchased from Biosystems (S.A.,
Costa Brava, Barcelona, Spain).
S Su ub bj je ec ct ts s
A total of 106 healthy volunteers (56 males, and
50 females), with an age range of 21-45 years and
having no history of alcohol abuse or diseases such
as diabetes mellitus or obesity, volunteered to par-
ticipate in the research after their consent was
obtained. Volunteers were excluded from the study
if they were on antioxidant or lipid-lowering med-
ication. The research has been carried out in accor-
dance with the Declaration of Helsinki (2000) of the
World Medical Association; and has been approved
by the Ethics Committee of the university. Subjects
were grouped according to their cigarette smoking
status into non-smokers (n = 51) and smokers 
(n = 55) groups. Smoking status was assigned
according to the following criteria: (1) at least 
21 years old, (2) daily smokers, (3) at least a 5-year
smoking history, (4) smoke at least 15 cigarettes
per day. Anthropometric measurements such as
height and weight were made following standard
techniques. 
B Bi io oc ch he em mi ic ca al l   t te es st ts s
Blood samples were drawn at about 9.00 am
after an overnight fast into heparinized Vacutain-
ers (BD Diagnostics, Franklin Lakes, NJ, USA). Fol-
lowing centrifugation for 10 min at 4°C, plasma frac-
tion was removed and stored at –80°C till analysis.
Fasting plasma glucose levels, total cholesterol
(TC), triglycerides (TG), HDL-C, total protein and
albumin were determined in all the subjects. Assays
were performed with a Dade Behring Dimension
RxL clinical chemistry system (Dade Behring; Ger-
many) using its own kits. LDL-cholesterol (LDL-C)
was calculated using the Friedewald’s formula [27].
The atherogenic ratio of TC/HDL-C as well as the
atherogenic index of plasma (AIP), calculated as log
(TG/HDL-C), with TG and HDL-C, were measured in
molar concentrations [28]. 
Total plasma coenzyme Q10 was measured by
reverse-phase  high  performance  liquid  chro-
matography (HPLC) with ultraviolet detection using
the method of Mosca et al. [29] with a slight mod-
ification. The method is based on oxidation of CoQ10
in the sample by treating it with para-benzo-
quinone. Coenzyme Q10 was then quantitatively
extracted into 1-propanol with a fast one-step
extraction procedure, after centrifugation, samples
were injected directly into the HPLC apparatus [30].
Pre-oxidation of the sample ensures quantification
of total CoQ10 by ultraviolet (UV) detection. The sep-
aration was performed using reversed-phase Supel-
cosil LC18 column (Supelco, Bellefonte, PA, USA).
The mobile phase was represented by ethanol-
methanol (65-35%). The flow rate was 1.5 ml/min
and UV detection was carried out at 275 nm. This
method achieves a linear detector response for
peak area measurements over the concentration
range of 0.05-3.47 ﾵM with a CV of 1.6% for sam-
ples approaching normal values (1.02 ﾵM). Supple-
mentation of the samples with known amounts of
CoQ10 yielded a quantitative recovery of 97.5-99%. 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s   
Results were expressed as mean ± standard devi-
ation. Statistical analysis was performed using an
unpaired t test with Welch's correction. Correlation
analysis was done using linear regression and Pear-
son’s correlation coefficient. Statistical significance
was defined by p < 0.05. All statistical tests were
two-tailed. Calculations were done using SPSS for
Windows (release 13.0, 2004; SPSS Inc., Chicago, IL). 
Results
A total of 106 subjects (50 females and 56 males)
met eligibility criteria and were grouped according
to cigarette smoking habit into a non-smoking
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group (n = 51) and a currently smoking group 
(n = 55). No significant differences in age, sex or
body mass index (BMI) were observed between
studied groups (Table I). 
Table II summarizes the main differences in the
measured parameters between studied groups. There
were no significant differences in plasma CoQ10 con-
centrations between male and female in the non-
P Pa ar ra am me et te er r G Ge en nd de er r N No on n- -s sm mo ok ke er rs s   ( (n n = =   5 51 1) ) S Sm mo ok ke er rs s   ( (n n = =   5 55 5) ) V Va al lu ue e   o of f   p pb b
Number (%) Female (n = 50) 25 (49%)  25 (45%) 0.845c
Male (n = 56) 26 (51%) 30 (55%)
Age [years]a Female (n = 50) 36.3 ±12.1 34.6 ±7.5 0.553
Male (n = 56) 34.3 ±12.7 35.1 ±12.7 0.815
Value of p 0.565 0.201c
BMI [kg/m2]a Female (n = 50) 24.2 ±3.0 25.5 ±3.3 0.153
Male (n = 56) 25.9±2.0 27.0 ±4.8 0.258
Value of p 0.863 0.177c
aResults are presented as mean ± SD, bp values are calculated by unpaired t-test with Welch's correction, cp value is calculated by Fisher's exact
test (2-sided)
T Ta ab bl le e   I I. . Age and body mass index (BMI) of female and male individuals for all groups
P Pa ar ra am me et te er ra a G Ge en nd de er r N No on n- -s sm mo ok ke er rs s   ( (n n = =   5 51 1) ) S Sm mo ok ke er rs s   ( (n n = =   5 55 5) ) V Va al lu ue e   o of f   p pb b
CoQ10 [ﾵmol/l]) Female (n = 50) 1.32 ±0.30 0.44 ±0.20 0.0001
Male (n = 56) 1.50 ±0.45 0.76 ±0.35 0.006
Value of p 0.053 0.003
Glucose [mmol/l] Female (n = 50) 5.60 ±0.60 6.20 ±1.90 0.141
Male (n = 56) 5.40 ±0.40 5.90 ±1.70 0.128
Value of p 0.178 0.548
Cholesterol Female (n = 50) 5.10 ±0.90 4.10 ±0.90 0.005
[mmol/l]
Male (n = 56) 4.90 ±0.80 4.70 ±1.13 0.44
Value of p 0.40 0.034
HDL-C [mmol/l] Female (n = 50) 1.39 ±0.31 0.90 ±0.12 0.0001
Male (n = 56) 1.29 ±0.29 1.03 ±0.26 0.02
Value of p 0.07 0.001
LDL-C [mmol/l] Female (n = 50) 2.95 ±0.33 2.02 ±0.46 0.001
Male (n = 56) 3.03 ±0.41 3.11 ±0.61 0.563
Value of p 0.48 0.001
Triglycerides  Female (n = 50) 1.69 ±0.54 2.02 ±0.44 0.003
[mmol/l]
Male (n = 56) 1.78 ±0.42 2.26 ±0.51 0.001
Value of p 0.164 0.105
AIP  Female (n = 50) 0.09 ±0.05 0.35 ±0.13 0.001
Male (n = 56) 0.13 ±0.09 0.34 ±0.11 0.001
Value of p 0.07 0.961
TC/HDL-C Female (n = 50) 3.67 ±1.10 4.56 ±1.53 0.026
Male (n = 56) 3.89 ±1.09 4.56 ±1.44 0.056
Value of p 0.523 0.967
CoQ10/LDL-C  Female (n = 50) 0.44 ±0.14 0.19 ±0.08 0.001
[ﾵmol/mmol]
Male (n = 56) 0.46 ±0.16 0.29 ±0.12 0.001
Value of p 0.45 0.001
AIP – The atherogenic index of plasma, defined as log(TG/HDL-C), aresults are presented as mean ± SD, bp values are calculated by unpaired
t test with Welch's correction
T Ta ab bl le e   I II I. .   Plasma coenzyme Q10 (CoQ10) and biochemical parameters in studied groups
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smoking group. In contrast, female smokers showed
significantly (p < 0.003) lower plasma CoQ10 levels
than  male  smokers.  In  addition,  plasma  CoQ10
concentrations were significantly lower in male 
(p < 0.006) and female (p < 0.0001) smokers com-
pared with their non-smoking counterparts. No sig-
nificant differences were found between the studied
groups regarding fasting blood glucose levels.
Regarding plasma cholesterol; female smokers
showed significantly decreased plasma concentra-
tions of total cholesterol compared with female
non-smokers  (p <  0.005)  and  male  smokers 
(p < 0.03). Regarding HDL-C, male smokers showed
significantly (p < 0.02) lower HDL-C than non-smok-
er males, whereas no significant differences were
found in HDL-C concentrations between male and
female non-smokers. Female smokers showed the
lowest concentrations of plasma HDL-C (0.9 ±0.12
mmol/l), which was significantly lower (p < 0.001)
than non-smoker females. No gender differences
were found in LDL-C concentrations between non-
smoker groups, however in smoker groups, females
showed  significantly  lower  LDL-C  than  males 
(p < 0.001). Female smokers showed also signifi-
cantly decreased LDL-C than non-smoker females
(p < 0.001). Men showed higher triglycerides than
women both in the non-smoking group and in the
smoker group, but this trend did not reach statisti-
cal significance, whereas smokers in both in male
and female groups showed significantly increased
triglycerides compared with their non-smoker coun-
terparts (p < 0.001 and 0.003, respectively). 
Table II also shows the average values of the athe  -
rogenic indices AIP, TC/HDL-C, and CoQ10/LDL-C. All
indices showed significant differences between
smokers and non-smokers irrespective of sex, but
CoQ10/LDL-C was the only index differing signifi-
cantly between female and male smokers (p < 0.001). 
Spearman’s correlation analyses of data are pre-
sented in Table III. Plasma CoQ10 concentrations
were significantly correlated with TC and LDL-C only
in female smokers. No correlations were observed
between CoQ10 and age, BMI, glucose, HDL-C, or
triglycerides. 
Discussion
Cigarette smoking has a negative impact on oxi-
dant defense systems not only through the pro-
duction of reactive oxygen species (ROS) in smoke
but also through the consumption of the body
reserve of antioxidants [31-33]. In addition to these
data, our results show that smoking has a negative
impact on the plasma levels of the antioxidant
CoQ10. These results support the assumption that
smo  king induced-oxidative stress may be the result
of, and/or the cause of, decreased plasma CoQ10 [33].
The impact of smoking on plasma CoQ10 was sig-
nificantly more marked in female than male smok-
ers (p < 0.003). The same trend has been reported
in previous studies which demonstrated that CoQ10
is affected by gender [25, 34]. This finding may pro-
vide an additional factor for the higher vulnerabili-
ty to the detrimental effects of cigarette smoking
in female compared with male smokers. Previous
studies have emphasized that females may respond
differently to tobacco-specific carcinogens based
on several factors, including that females having
higher DNA adduct levels, an increased CYP1A1
expression, a decreased DNA repair capacity and an
increased incidence of K-ras gene mutations [35-38]. 
Additional factors have been suggested to con-
tribute to interindividual susceptibility to smoking-
related morbidity and mortality including BMI [39],
age [40], and total cholesterol [41]. Therefore, we
studied these parameters in relation to plasma
CoQ10 concentrations of healthy smokers and non-
smokers. In agreement with Wolters and Hahn
study [42], no significant correlation was found
between CoQ10 levels and BMI or age. However,
results of the present study show that smoking is
associated with abnormal lipid profile, and that
these abnormalities were more significantly evident
P Pa ar ra am me et te er ra a G Gr ro ou up p N No on n- -s sm mo ok ke er rs s S Sm mo ok ke er rs s
( (n n = =   5 51 1) ) ( (n n = =   5 55 5) )
Age [years] Female (n = 50) 0.196 0.399
Male (n = 56) –0.22 0.106
BMI [kg/m2] Female (n = 50) 0.400 0.477
Male (n = 56) 0.321 0.326
Glucose  Female (n = 50) 0.107 0.342
[mmol/l]
Male (n = 56) 0.024 0.333
Cholesterol  Female (n = 50) 0.258 0.630***
[mmol/l]
Male (n = 56) 0.397* 0.301
HDL-C  Female (n = 50) –0.266 0.093
[mmol/l]
Male (n = 56) 0.090 0.209
LDL-C  Female (n = 50) 0.199 0.577**
[mmol/l]
Male (n = 56) 0.426* 0.031
Triglycerides  Female (n = 50) 0.477** –0.182
[mmol/l]
Male (n = 56) –0.030 0.297
AIP  Female (n = 50) 0.238 0.334
Male (n = 56) 0.182 0.271
TC/HDL-C Female (n = 50) 0.158 0.397
Male (n = 56) 0.224 0.309
CoQ10/LDL-C  Female (n = 50) 0.274 0.596***
[ﾵmol/mmol]
Male (n = 56) 0.146 0.466**
aResults are presented as a correlation coefficient, *significant at 
p < 0.05, **significant at p < 0.01, ***significant at p < 0.001
T Ta ab bl le e   I II II I. .   The correlation between plasma coenzyme
Q10 (CoQ10) and biochemical parameters in studied
groups
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in female than male smokers. Female smokers
exhibited significantly lower TC, LDL-C,  and HDL-C
values than both female non-smokers (p < 0.005;
p < 0.024; p < 0.0001 respectively), and male smok-
ers (p < 0.03; p < 0.042; p < 0.028 respectively).
These findings are in agreement with a previous
study in women aged less than 50 years [43]. These
findings are in agreement with the Munster Heart
Study (PROCAM) [44] and the Framingham Study
[45] which reported decreased TC and LDL-C con-
centrations in smokers but not in non-smokers.
These studies have also found evidence that total
mortality in middle-aged men is increased at low
TC and LDL-C concentrations in smokers but not in
non-smokers [44, 45]. 
The relationship between serum TC level and
mortality rate was found U-shaped as a result of
a U-shaped association with mortality from infec-
tious diseases, a negative association with mortal-
ity from cancer and alcohol-related diseases, and
a positive association with mortality from cardio-
vascular diseases and diabetes/nephropathy. Accu-
mulated evidence suggests that a low cholesterol
level may be a metabolic consequence of cancer
rather than a precursor [46]. Moreover, increasing
evidence now suggests that low cholesterol levels
are  associated  with  not  only  cancer,  but  also
adverse effects on the brain causing neuropsychi-
atric syndromes [47] and haemorrhagic stroke [48].
In the present study, results showed a significant
positive correlation between CoQ10 plasma con-
centrations and TC and LDL-C (both at p < 0.001)
only in female smokers. This relationship suggests
that those subjects with lower TC and LDL-C, as in
the situation of female smokers, are more likely to
have lower CoQ10, and therefore could be more
prone to cancer, infectious and brain diseases lat-
er in their life.
Moreover, these data are in agreement with ear-
lier  studies  demonstrating  a close  connection
between CoQ10 and plasma lipids, as about 60% of
plasma CoQ10 is associated with LDL-C, and that
CoQ10 is mainly associated with plasma lipids rather
than with cellular components [49, 50]. 
Numerous studies have indicated that LDL-C is
associated with atherosclerosis plaque initiation
and vulnerability to rupture, while cigarette smok-
ing is more associated with plaque progression [51].
The atherogenic index of plasma (AIP) that has
been suggested as a marker of plasma athero-
genicity [28], was found in the present study to be
significantly higher in male and female smokers 
(p < 0.001). We further tested whether this trend is
valid  for  other  proposed  atherogenic  indices
TC/HDL-C and TG/HDL-C [52, 53]. Both indices were
found significantly higher in smokers than non-
smokers irrespective of sex. 
Studies have proposed the ratio CoQ10/LDL-C
as a sensitive marker for development of athero-
sclerotic changes and coronary artery disease [50,
54, 55]. In our study, this ratio was significantly low-
er in smokers compared with non-smokers; how-
ever it was significantly lower in female smokers
compared with male smokers suggesting that
female smokers may be at increased risk of devel-
oping atherosclerosis. In addition, this finding may
provide an additional clarification for previous find-
ings of a much stronger association between smok-
ing and coronary heart disease in women than
men [51], which was attributable to arteriolar dif-
ferences [51, 56].
In  conclusion,  this  study  suggests  that  the
adverse effects of smoking are greater in females
than in males, partially as a result of decreased
CoQ10 plasma concentrations, HDL-C and total-cho-
lesterol and abnormal atherogencity indices. There
is clearly a need for further large-scale studies to
be designed in such a way that they are sensitive
to a range of factors that contribute to gender dif-
ference in susceptibility to smoking. 
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